Published in Nat Genet on December 01, 1995
The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol (2001) 2.83
Genotype-phenotype relationships involving hypertrophic cardiomyopathy-associated mutations in titin, muscle LIM protein, and telethonin. Mol Genet Metab (2005) 2.72
Cardiac myosin-binding protein-C phosphorylation and cardiac function. Circ Res (2005) 2.67
Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med (2008) 2.12
Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes. Heart Fail Rev (2005) 2.10
Expression and functional assessment of a truncated cardiac troponin T that causes hypertrophic cardiomyopathy. Evidence for a dominant negative action. J Clin Invest (1996) 2.09
Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice. J Clin Invest (1999) 2.02
Genetics of human cardiovascular disease. Cell (2012) 1.90
In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament. Circ Res (2011) 1.81
Differential roles of regulatory light chain and myosin binding protein-C phosphorylations in the modulation of cardiac force development. J Physiol (2010) 1.76
Mutations in JPH2-encoded junctophilin-2 associated with hypertrophic cardiomyopathy in humans. J Mol Cell Cardiol (2007) 1.70
A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy. J Clin Invest (1998) 1.65
Effect of MyBP-C binding to actin on contractility in heart muscle. J Gen Physiol (2003) 1.62
A cardiac myosin light chain kinase regulates sarcomere assembly in the vertebrate heart. J Clin Invest (2007) 1.61
Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history. Circ Res (2011) 1.58
Altered cardiac troponin T in vitro function in the presence of a mutation implicated in familial hypertrophic cardiomyopathy. J Clin Invest (1996) 1.57
Mice expressing mutant myosin heavy chains are a model for familial hypertrophic cardiomyopathy. Mol Med (1996) 1.54
HEART DISEASE. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy. Science (2015) 1.52
An X-linked myopathy with postural muscle atrophy and generalized hypertrophy, termed XMPMA, is caused by mutations in FHL1. Am J Hum Genet (2008) 1.49
Dominant-negative effect of a mutant cardiac troponin T on cardiac structure and function in transgenic mice. J Clin Invest (1998) 1.47
Haploinsufficiency of MYBPC3 exacerbates the development of hypertrophic cardiomyopathy in heterozygous mice. J Mol Cell Cardiol (2014) 1.47
Modifier genes for hypertrophic cardiomyopathy. Curr Opin Cardiol (2002) 1.47
Echocardiographic pitfalls in the diagnosis of hypertrophic cardiomyopathy. Heart (1999) 1.45
Altered patterns of cardiac intercellular junction distribution in hypertrophic cardiomyopathy. Heart (1996) 1.41
Electron microscopy and 3D reconstruction of F-actin decorated with cardiac myosin-binding protein C (cMyBP-C). J Mol Biol (2011) 1.37
Endothelin-induced conversion of embryonic heart muscle cells into impulse-conducting Purkinje fibers. Proc Natl Acad Sci U S A (1998) 1.37
Novel splice donor site mutation in the cardiac myosin-binding protein-C gene in familial hypertrophic cardiomyopathy. Characterization Of cardiac transcript and protein. J Clin Invest (1997) 1.36
Myosin binding protein C1: a novel gene for autosomal dominant distal arthrogryposis type 1. Hum Mol Genet (2010) 1.32
Molecular and functional characterization of novel hypertrophic cardiomyopathy susceptibility mutations in TNNC1-encoded troponin C. J Mol Cell Cardiol (2008) 1.30
Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: insights into disease pathogenesis and troponin function. Proc Natl Acad Sci U S A (1998) 1.29
Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. J Med Genet (2013) 1.27
The role of palladin in actin organization and cell motility. Eur J Cell Biol (2008) 1.22
Signaling and myosin-binding protein C. J Biol Chem (2011) 1.18
Hypertrophic cardiomyopathy: from genetics to treatment. Eur J Clin Invest (2010) 1.17
MYBPH, a transcriptional target of TTF-1, inhibits ROCK1, and reduces cell motility and metastasis. EMBO J (2011) 1.17
Vertebrate isoforms of actin capping protein beta have distinct functions In vivo. J Cell Biol (1999) 1.15
A new mutation of the cardiac troponin T gene causing familial hypertrophic cardiomyopathy without left ventricular hypertrophy. Heart (1999) 1.14
Characterization of mutant myosins of Dictyostelium discoideum equivalent to human familial hypertrophic cardiomyopathy mutants. Molecular force level of mutant myosins may have a prognostic implication. J Clin Invest (1997) 1.12
Contemporary treatment of hypertrophic cardiomyopathy. Tex Heart Inst J (2009) 1.12
Roles for cardiac MyBP-C in maintaining myofilament lattice rigidity and prolonging myosin cross-bridge lifetime. Biophys J (2011) 1.11
Functional analysis of myosin mutations that cause familial hypertrophic cardiomyopathy. Biophys J (1998) 1.04
Myosin filament 3D structure in mammalian cardiac muscle. J Struct Biol (2008) 1.03
Cytoplasmic Ig-domain proteins: cytoskeletal regulators with a role in human disease. Cell Motil Cytoskeleton (2009) 1.02
Molecular genetics and pathogenesis of hypertrophic cardiomyopathy. Minerva Med (2001) 1.00
Molecular pathology of familial hypertrophic cardiomyopathy caused by mutations in the cardiac myosin binding protein C gene. J Med Genet (1998) 0.97
Molecular effects of familial hypertrophic cardiomyopathy-related mutations in the TNT1 domain of cTnT. J Mol Biol (2012) 0.97
An endogenously produced fragment of cardiac myosin-binding protein C is pathogenic and can lead to heart failure. Circ Res (2013) 0.96
Myosin binding protein-C: a regulator of actomyosin interaction in striated muscle. J Biomed Biotechnol (2011) 0.95
Beyond the cardiac myofilament: hypertrophic cardiomyopathy- associated mutations in genes that encode calcium-handling proteins. Curr Mol Med (2012) 0.94
Cardiac myosin binding protein-C as a central target of cardiac sarcomere signaling: a special mini review series. Pflugers Arch (2013) 0.93
Cardiac myosin binding protein C insufficiency leads to early onset of mechanical dysfunction. Circ Cardiovasc Imaging (2011) 0.92
Contractile dysfunction in a mouse model expressing a heterozygous MYBPC3 mutation associated with hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol (2014) 0.92
Trinucleotide insertions, deletions, and point mutations in glucose transporters confer K+ uptake in Saccharomyces cerevisiae. Mol Cell Biol (1998) 0.91
A novel variant of cardiac myosin-binding protein-C that is unable to assemble into sarcomeres is expressed in the aged mouse atrium. Mol Biol Cell (2003) 0.89
Multiple forms of cardiac myosin-binding protein C exist and can regulate thick filament stability. J Gen Physiol (2007) 0.89
MYBPC1 mutations impair skeletal muscle function in zebrafish models of arthrogryposis. Hum Mol Genet (2013) 0.88
Modulation of striated muscle contraction by binding of myosin binding protein C to actin. Bioarchitecture (2011) 0.87
Subclinical echocardiographic abnormalities in phenotype-negative carriers of myosin-binding protein C3 gene mutation for hypertrophic cardiomyopathy. Am Heart J (2011) 0.86
Mendelian-inherited heart disease: a gateway to understanding mechanisms in heart disease Update on work done at the University of Stellenbosch. Cardiovasc J Afr (2009) 0.86
Identification of a new missense mutation in MyBP-C associated with hypertrophic cardiomyopathy. J Med Genet (1998) 0.86
Screening mutations in myosin binding protein C3 gene in a cohort of patients with Hypertrophic Cardiomyopathy. BMC Med Genet (2010) 0.86
Unexpectedly low mutation rates in beta-myosin heavy chain and cardiac myosin binding protein genes in Italian patients with hypertrophic cardiomyopathy. J Cell Physiol (2011) 0.85
MYBPC3's alternate ending: consequences and therapeutic implications of a highly prevalent 25 bp deletion mutation. Pflugers Arch (2013) 0.85
Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it all. Expert Rev Mol Diagn (2010) 0.85
On genetic and phenotypic variability of hypertrophic cardiomyopathy: nature versus nurture. J Am Coll Cardiol (2001) 0.84
MiR-451 is decreased in hypertrophic cardiomyopathy and regulates autophagy by targeting TSC1. J Cell Mol Med (2014) 0.84
Cardiac myosin binding protein-C plays no regulatory role in skeletal muscle structure and function. PLoS One (2013) 0.84
Structure and function of palladin's actin binding domain. J Mol Biol (2013) 0.83
Modulation of thin filament activation of myosin ATP hydrolysis by N-terminal domains of cardiac myosin binding protein-C. Biochemistry (2014) 0.83
Cardiac troponin structure-function and the influence of hypertrophic cardiomyopathy associated mutations on modulation of contractility. Arch Biochem Biophys (2016) 0.82
The rare association of tetralogy of Fallot with hypertrophic cardiomyopathy. Report of 2 neonatal patients. Tex Heart Inst J (1997) 0.82
Cardiac myosin-binding protein C: hypertrophic cardiomyopathy mutations and structure-function relationships. Pflugers Arch (2013) 0.81
A hypertrophic cardiomyopathy-associated MYBPC3 mutation common in populations of South Asian descent causes contractile dysfunction. J Biol Chem (2015) 0.80
MYBPC3 in hypertrophic cardiomyopathy: from mutation identification to RNA-based correction. Pflugers Arch (2013) 0.80
To screen or not is not the question--it is when and how to screen. Circulation (2003) 0.79
A previously undescribed de novo insertion-deletion mutation in the beta myosin heavy chain gene in a kindred with familial hypertrophic cardiomyopathy. Heart (1996) 0.79
Myosin binding protein C: implications for signal-transduction. J Muscle Res Cell Motil (2011) 0.79
Reduction of left ventricular longitudinal global and segmental systolic functions in patients with hypertrophic cardiomyopathy: Study of two-dimensional tissue motion annular displacement. Exp Ther Med (2014) 0.79
Sizing up models of heart failure: Proteomics from flies to humans. Proteomics Clin Appl (2014) 0.78
Ablation of cardiac myosin binding protein-C disrupts the super-relaxed state of myosin in murine cardiomyocytes. J Mol Cell Cardiol (2016) 0.78
Targeted Mybpc3 Knock-Out Mice with Cardiac Hypertrophy Exhibit Structural Mitral Valve Abnormalities. J Cardiovasc Dev Dis (2015) 0.77
C0 and C1 N-terminal Ig domains of myosin binding protein C exert different effects on thin filament activation. Proc Natl Acad Sci U S A (2016) 0.76
Cardiac Troponin and Tropomyosin: Structural and Cellular Perspectives to Unveil the Hypertrophic Cardiomyopathy Phenotype. Front Physiol (2016) 0.76
Three-dimensional structure of the human myosin thick filament: clinical implications. Glob Cardiol Sci Pract (2013) 0.75
Synchronous in situ ATPase activity, mechanics, and Ca2+ sensitivity of human and porcine myocardium. Biophys J (2009) 0.75
Knockdown of fast skeletal myosin-binding protein C in zebrafish results in a severe skeletal myopathy. J Gen Physiol (2016) 0.75
Amino Acid Changes at Arginine 204 of Troponin I Result in Increased Calcium Sensitivity of Force Development. Front Physiol (2016) 0.75
Cardiomyopathy classification: ongoing debate in the genomics era. Biochem Res Int (2012) 0.75
Mechanotransduction and Metabolism in Cardiomyocyte Microdomains. Biomed Res Int (2016) 0.75
A Novel Method of Determining the Functional Effects of a Minor Genetic Modification of a Protein. Front Cardiovasc Med (2015) 0.75
The phenotype/genotype relation and the current status of genetic screening in hypertrophic cardiomyopathy, Marfan syndrome, and the long QT syndrome. Heart (1997) 0.75
Mendelian forms of structural cardiovascular disease. Curr Cardiol Rep (2013) 0.75
Recent advances. Medical genetics. BMJ (1996) 0.75
Prevalence and Phenotypic Expression of Mutations in the MYH7, MYBPC3 and TNNT2 Genes in Families with Hypertrophic Cardiomyopathy in the South of Brazil: A Cross-Sectional Study. Arq Bras Cardiol (2016) 0.75
Screening Mutations of MYBPC3 in 114 Unrelated Patients with Hypertrophic Cardiomyopathy by Targeted Capture and Next-generation Sequencing. Sci Rep (2015) 0.75
A One Health Approach to Hypertrophic Cardiomyopathy. Yale J Biol Med (2017) 0.75
Identification of pathogenic gene mutations in LMNA and MYBPC3 that alter RNA splicing. Proc Natl Acad Sci U S A (2017) 0.75
MYBPC3 mutations are associated with a reduced super-relaxed state in patients with hypertrophic cardiomyopathy. PLoS One (2017) 0.75
Experimental Modeling Supports a Role for MyBP-HL as a Novel Myofilament Component in Arrhythmia and Dilated Cardiomyopathy. Circulation (2017) 0.75
Sequences of five potential recombination sites encoded close to an immunoglobulin kappa constant region gene. Proc Natl Acad Sci U S A (1979) 9.31
Cloned human and mouse kappa immunoglobulin constant and J region genes conserve homology in functional segments. Cell (1980) 8.77
Identification of a putative second T-cell receptor. Nature (1986) 7.90
Clinical profile of congenital coronary artery anomalies with origin from the wrong aortic sinus leading to sudden death in young competitive athletes. J Am Coll Cardiol (2000) 7.39
Production of homozygous mutant ES cells with a single targeting construct. Mol Cell Biol (1992) 7.23
Mouse beta 2-microglobulin cDNA clones: a screening procedure for cDNA clones corresponding to rare mRNAs. Proc Natl Acad Sci U S A (1981) 6.67
A kappa-immunoglobulin gene is formed by site-specific recombination without further somatic mutation. Nature (1979) 6.54
Truncations of titin causing dilated cardiomyopathy. N Engl J Med (2012) 6.07
Congenital heart disease caused by mutations in the transcription factor NKX2-5. Science (1998) 5.98
A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease. Cell (2001) 5.77
A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell (1990) 5.77
Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med (1999) 5.61
Cloning specific segments of the mammalian genome: bacteriophage lambda containing mouse globin and surrounding gene sequences. Proc Natl Acad Sci U S A (1977) 5.28
Polony multiplex analysis of gene expression (PMAGE) in mouse hypertrophic cardiomyopathy. Science (2007) 5.19
Mutations in human TBX5 [corrected] cause limb and cardiac malformation in Holt-Oram syndrome. Nat Genet (1997) 5.11
Antibody diversity. Science (1978) 5.06
An experimental model of sudden death due to low-energy chest-wall impact (commotio cordis) N Engl J Med (1998) 4.92
The arrangement and rearrangement of antibody genes. Nature (1979) 4.88
Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet (2000) 4.54
Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation (2003) 4.48
Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell (1994) 4.47
Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med (1995) 4.37
Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med (2000) 4.30
Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med (1998) 4.29
Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med (1992) 4.20
The management of hypertrophic cardiomyopathy. N Engl J Med (1997) 4.15
Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell (1993) 4.13
Intervening sequence of DNA identified in the structural portion of a mouse beta-globin gene. Proc Natl Acad Sci U S A (1978) 4.02
Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med (2000) 3.99
Mutations in human TBX3 alter limb, apocrine and genital development in ulnar-mammary syndrome. Nat Genet (1997) 3.91
Multiple related immunoglobulin variable-region genes identified by cloning and sequence analysis. Proc Natl Acad Sci U S A (1978) 3.88
A T-cell receptor gamma/CD3 complex found on cloned functional lymphocytes. Nature (1987) 3.81
Structure and expression of a mouse major histocompatibility antigen gene, H-2Ld. Proc Natl Acad Sci U S A (1982) 3.73
Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science (2003) 3.71
Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med (2005) 3.71
A mouse model of familial hypertrophic cardiomyopathy. Science (1996) 3.69
Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol (1997) 3.64
Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med (2010) 3.42
High capacity gel preparative electrophoresis for purification of fragments of genomic DNA. Anal Biochem (1978) 3.42
Transcription of mouse kappa chain genes: implications for allelic exclusion. Proc Natl Acad Sci U S A (1980) 3.38
Two forms of the T-cell receptor gamma protein found on peripheral blood cytotoxic T lymphocytes. Nature (1987) 3.37
The genetic basis for cardiac remodeling. Annu Rev Genomics Hum Genet (2005) 3.36
Profile of preparticipation cardiovascular screening for high school athletes. JAMA (1998) 3.36
Exon shuffling: mapping polymorphic determinants on hybrid mouse transplantation antigens. Nature (1982) 3.34
Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest (2002) 3.33
A human MSX1 homeodomain missense mutation causes selective tooth agenesis. Nat Genet (1996) 3.24
Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation (2002) 3.22
Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation (2002) 3.20
A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat Genet (1995) 3.18
The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes. N Engl J Med (1991) 3.17
Sudden death in young athletes. Circulation (1980) 3.05
Side effects of long-term amiodarone therapy. Circulation (1983) 3.03
Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet (2001) 3.02
Structure of wild-type and mutant mouse beta 2-microglobulin genes. Cell (1982) 2.97
Mutations in the cardiac transcription factor NKX2.5 affect diverse cardiac developmental pathways. J Clin Invest (1999) 2.95
Progression to diabetes in nonobese diabetic (NOD) mice with transgenic T cell receptors. Science (1993) 2.94
Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J (2001) 2.93
Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol (2000) 2.89
Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). N Engl J Med (1987) 2.88
Shared human T cell receptor V beta usage to immunodominant regions of myelin basic protein. Science (1990) 2.86
The clinical and genetic spectrum of the Holt-Oram syndrome (heart-hand syndrome) N Engl J Med (1994) 2.82
Filter-based hybridization capture of subgenomes enables resequencing and copy-number detection. Nat Methods (2009) 2.71
Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med (1989) 2.70
Different TBX5 interactions in heart and limb defined by Holt-Oram syndrome mutations. Proc Natl Acad Sci U S A (1999) 2.70
Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy. Circulation (1979) 2.68
Novel organ-specific circulating cardiac autoantibodies in dilated cardiomyopathy. J Am Coll Cardiol (1990) 2.67
Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat Genet (2002) 2.67
Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol (1995) 2.62
Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients. Circulation (1989) 2.56
An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. J Clin Invest (2000) 2.56
Delay to invasive investigation and revascularisation for coronary heart disease in south west Thames region: a two tier system? BMJ (1991) 2.48
Cardiac fatigue following prolonged endurance exercise of differing distances. Med Sci Sports Exerc (2000) 2.47
Expression of H-2Dd and H-2Ld mouse major histocompatibility antigen genes in L cells after DNA-mediated gene transfer. J Immunol (1983) 2.45